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Abstract
Introduction: The objective of this study was to identify and characterize the most highly cited clinical research
articles published on sepsis.
Methods: A comprehensive list of citation classics in sepsis was generated by searching the database of Web of
Science-Expanded (1970 to present) using keywords ‘sepsis’ or ‘septic shock’. The top 50 cited clinical research
papers were retrieved by reading the abstract or full text if needed. Each eligible article was reviewed for basic
information, including country of origin, article type, journals, authors, and funding sources.
Results: A total of 2,151 articles were cited more than 100 times; the 50 top-cited clinical articles were published
between 1974 and 2008. The number of citations ranged from 372 to 2,932, with a mean of 678 citations per
article. These citation classics came from nine countries, of which 26 articles came from the United States. Rush
University and the University of Pittsburgh lead the list of classics with six papers each. The 50 top-cited articles
were published in 17 journals, with the New England Journal of Medicine and Journal of the American Medical
Association topping the list. The top 50 articles consisted of 21 clinical trials and 29 observational studies.
Conclusions: Our bibliometric analysis provides a historical perspective on the progress of clinical research on
sepsis. Articles originating from the United States and published in high-impact journals are most likely to be cited
in the field of sepsis research.
Introduction
Sepsis is a systemic inflammatory response syndrome
that occurs during severe infection. It remains a leading
cause of death in critically ill patients [1]. Numerous cri-
tical care and infectious disease specialists and research-
ers have focused their efforts on sepsis in an attempt to
gain a better understanding of the pathophysiological
basis of sepsis or to develop new methods for the diag-
nosis and treatment of sepsis. Large numbers of articles
have been published annually and have given new
insights into the mechanism or treatment of sepsis [2].
It is generally accepted that publications represent the
central part of a research process. Citation rating is a
popular method for evaluating the impact of an investi-
gator or a publication in the scientific community con-
cerned. The frequency of citing has significant
implications for authors, journals, institutions and even
nations[3]. A remarkable citation history of an author
often signifies great honor or recognition in a particular
area of research. Although there are obvious disadvan-
tages in assessing the quality of a study simply based on
the citation rating, it is widely accepted that this is the
best method currently available for judging the merit of
a paper or a journal [4]. Citation analysis is also a feasi-
ble tool to comprehensively recognize the research
advances in the past and future research trends in a spe-
cific field.
Clinical research refers to research conducted with
human beings, including studies in patient-oriented
research, epidemiological and behavioral studies, out-
comes and health service research. Clinical study plays a
special role in the fight against sepsis because it can
provide overwhelming evidence for the treatment and
diagnoses of a disease or disorder. Analysis of the most
cited articles allows clinical investigators to identify the
most popular field of research in sepsis and will give us
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insights into the characteristics and quality that are
required for an article to become widely cited.
Recently, various specialties have attempted to sum-
marize ‘citation classics’ or the most commonly cited
articles in their fields [5-8]. In order to systematically
review the citation classics dedicated to sepsis, we con-
ducted the current study to focus exclusively on the 50
top cited clinical articles in an attempt to provide a bib-
liometric perspective of the progress in sepsis research.
We also intended to identify factors contributing to the
successful citation such as journals in which the articles
were published and related countries.
Materials and methods
The database of the Institute for Scientific Information
(ISI) Web of Science Expanded citation index (1970 to
present) was searched using the keyword ‘sepsis’ or ‘sep-
tic shock’ to identify the citation classics cited more
than 400 times. This database includes peer-reviewed
publications indexed from more than 10,000 high
impact journals worldwide. The ‘document type’ was
applied to limit the format of publications and the type
of articles. Papers published as ‘article’ were selected for
further analysis. Each article on the list was reviewed by
reading the abstract first and only studies dedicated to
clinical research on sepsis were selected for further ana-
lysis. The following information was recorded: authors,
the number of citations, year of publication, country of
origin, institution, journal, funding source, and article
type or subfield (for example, randomized controlled
trials, observational research). We also calculated the
publication output on sepsis by normalizing the total
number of articles to the gross domestic product (GDP)
per capita of the included countries. The information of
GDP per capita was retrieved from the website of the
World Bank. All electronic searches were conducted on
13 March 2012. Correlation analysis between GDP per
capita and the total number of articles on sepsis was
conducted using GraphPad Prism 5.0 software.
Results
A total of 67,558 papers were identified in the initial
search for the period from 1970 to present, with 50,192
published as ‘article’ and 4,748 classified as ‘review’.
Among them, 2,151 articles were cited more than 100
times.
Of the top 50 cited clinical trials, the mean number of
citations was 678 (range 372 to 2,932) and six papers
were cited more than 1,000 times (Table 1). These arti-
cles were published between 1974 and 2008, of which
about 50% were published after 1995 (Table 2).
The 50 top cited articles originated from nine coun-
tries, with the United States (26) and France (8) being
the most prolific (Table 3). Given some articles were
authored with multiple sources of origin, especially
those in the form of international research collabora-
tions, the country of origin was defined by the address
of the corresponding author. The leading institutions
are shown in Table 4. Rush University and the Univer-
sity of Pittsburgh were found to be the most productive
institutions, with six articles each. There was a weak
correlation between the GDP per capita and the num-
bers of articles on sepsis related to the nine countries
(r2 = 0.02).
The 50 top cited clinical articles were published in 17
journals, predominantly in New England Journal of Med-
icine (n = 11) and Journal of the American Medical
Association (n = 11), followed by Critical Care Medicine
(n = 6) (Table 5). Table 6 presents a list of the most
productive authors, indicating that Sprung CL authored
six articles, followed by Abraham E, Bone RC, Fisher CJ
and Vincent JL.
Subgroup analysis of the top cited studies indicated
that biomarkers (10, 11, 15, 21, 22, 26, 27, 30, 34, 40 in
Table 1), immunology (6, 14, 17, 18, 20, 24, 28, 32, 37,
45 in Table 1), hemodynamics (2, 9, 12, 16, 19, 39, 47,
49 in Table 1), steroids (5, 7, 29, 31, 33, 35, 36 in Table
1) and epidemiology (3, 4, 8, 23, 25, 38, 50 in Table 1)
were the most popular topics.
Of the 50 top cited articles, 21 reported clinical trials,
of which 19 were designed as randomized controlled
trials (RCT) and 29 reported observational studies.
Among these original research papers, 15 were funded
by public foundations, 12 received support from com-
mercial companies, six were supported by both, and for
the remaining 17 the funding source was not specified
(Table 7). Specifically, five studies received grants from
the National Institutes of Health (NIH). Eight of the 19
RCTs reported supportive interventions and 11 studies
showed detrimental or neutral effects [See Additional
file 1].
Discussion
The present study summarizes several features of influ-
ential articles in sepsis research during the past 40 years
by means of a literature review. It was found that 26
(52%) of the 50 articles were from the United States.
The country dominance is also found in other clinical
disciplines including Urology [5], Orthopedic Surgery
[6], Critical Care Medicine [7], General Surgery [8],
Emergency Medicine [9] and Anesthesia [10]. The
underlying reasons might be due to its large population
of senior researchers and adequate research budgets for
scientific investigation. It is generally presumed that the
correlation between the research output and GDP
should be an important issue in bibliometric analysis.
But we found that the correlation between the GDP per
capita and the total number of articles published on
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Table 1 The top 50 cited clinical trials on sepsis.
Ratings Article No. of
citations
1 Bernard GR, Vincent JL, Laterre P, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely
EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. New England
Journal of Medicine 2001, 344:699-709.
2932
2 Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early Goal-Directed Therapy C:
Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine 2001,
345:1368-1377.
2538
3 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United
States: Analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 2001, 29(7):1303-1310.
2158
4 Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000.
New England Journal of Medicine 2003, 348:1546-1554.
1551
5 Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-
Riffaud P, Bellissant E: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in
patients with septic shock. JAMA-Journal of the American Medical Association 2002, 288:862-871.
1227
6 Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN: Treatment of
gram-negative bacteremia and septic shock with HA-1a human monoclonal-antibody against endotoxin - a
randomized, double-blind, placebo-controlled trial. New England Journal of Medicine 1991, 324:429-436.
1152
7 Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA: A controlled clinical-trial of high-dose
methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine 1987,
317:653-658.
902
8 Rangelfrausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural-history of the systemic inflammatory
response syndrome (SIRS) - a prospective-study. JAMA-Journal of the American Medical Association 1995, 273:117-123.
827
9 Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S,
Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler
M, Reinhart K: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. New England Journal of
Medicine 2008, 358:125-139.
738
10 Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis
syndrome. Annals of Internal Medicine 1993, 119:771-778.
729
11 Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C: High serum procalcitonin concentrations in patients
with sepsis and infection. Lancet 1993, 341:515-518.
693
12 Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but
reversible myocardial depression in patients with septic shock. Annals of Internal Medicine 1984, 100:483-490.
655
13 Kudsk KA, Croce MA, Fabian TC, Minard G, Tolley EA, Poret HA, Kuhl MR, Brown RO: Enteral versus parenteral-feeding -
effects on septic morbidity after blunt and penetrating abdominal-trauma. Annals of Surgery 1992, 215:503-513.
650
14 Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock
with the tumor necrosis factor receptor:Fc fusion protein. New England Journal of Medicine 1996, 334:1697-1702.
649
15 Hack CE, Degroot ER, Feltbersma RJF, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA:
Increased plasma-levels of interleukin-6 in sepsis. Blood 1989, 74:1704-1710.
643
16 Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A,
Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant
of survival in human septic shock. Critical Care Medicine 2006, 34(6):1589-1596.
598
17 Fisher CJ, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL:
Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome - results
from a randomized, double-blind, placebo-controlled trial. JAMA-Journal of the American Medical Association 1994, 271
(23):1836-1843.
591
18 Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J:
A controlled clinical-trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative
sepsis. JAMA-Journal of the American Medical Association 1991, 266:1097-1102.
564
19 Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO,
Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM: High-dose a randomized antithrombin III in severe sepsis - A
randomized controlled trial. JAMA-Journal of the American Medical Association 2001, 286:1869-1878.
552
20 Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic
patients: Restoration by IFN-gamma treatment. Nature Medicine 1997, 3:678-681.
510
21 Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E: Serum cytokine levels in human septic shock - relation
to multiple-system organ failure and mortality. Chest 1993, 103:565-575.
506
22 Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL, Peitzman AB: Nitrogen-oxide levels in patients after
trauma and during sepsis. Annals of Surgery 1991, 214:621-626.
505
23 Brunbuisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B: Incidence, risk-
factors, and outcome of severe sepsis and septic shock in adults - a multicenter prospective-study in intensive-
care units. JAMA-Journal of the American Medical Association 1995, 274:968-974.
498
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Table 1 The top 50 cited clinical trials on sepsis. (Continued)
24 Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R: Efficacy and
safety of monoclonal-antibody to human tumor-necrosis-factor-alpha in patients with sepsis syndrome - a
randomized, controlled, double-blind, multicenter clinical-trial. JAMA-Journal of the American Medical Association 1995,
273:934-941.
491
25 Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W,
Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK: Late-onset sepsis in very low birth
weight neonates: The experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110:285-291.
490
26 Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP: Prognostic values of
tumor-necrosis-factor cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients
with septic shock. Journal of Infectious Diseases 1990, 161:982-987.
473
27 Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M: Cytokine serum level during severe sepsis
in human IL-6 as a marker of severity. Annals of Surgery 1992, 215:356-362.
465
28 Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in
patients with sepsis, shock, and multiple organ dysfunction. Critical Care Medicine 1999, 27:1230-1251.
463
29 Sprung CL, Caralis PV, Marcial EH, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: The effects of high-dose
corticosteroids in patients with septic shock - a prospective, controlled-study. New England Journal of Medicine 1984,
311:1137-1143.
461
30 Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 1991, 99:169-
175.
458
31 Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF,
Reinhart K, Cuthbertson BH, Payen D, Briegel J: Hydrocortisone therapy for patients with septic shock. New England
Journal of Medicine 2008, 358:111-124.
458
32 Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, MacLean LD: Delayed-hypersensitivity - indicator of
acquired failure of host defenses in sepsis and trauma. Annals of Surgery 1977, 186:241-250.
449
33 Annane D, Sebille V, Troche G, Raphaël JC, Gajdos P, Bellissant E: A 3-level prognostic classification in septic shock
based on cortisol levels and cortisol response to corticotropin. JAMA-Journal of the American Medical Association 2000,
283:1038-1045.
444
34 Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM: High bronchoalveolar levels of tumor-necrosis-factor
and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory-distress syndrome after
trauma, shock, or sepsis. American Review of Respiratory Disease 1992, 145:1016-1022.
443
35 Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K:
Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind,
single-center study. Critical Care Medicine 1999, 27:723-732.
426
36 Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with
supraphysiologic doses of hydrocortisone. Critical Care Medicine 1998, 26:645-650.
425
37 Munoz C, Carlet J, Fitting C, Misset B, Blériot JP, Cavaillon JM: Dysregulation of invitro cytokine production by
monocytes during sepsis. Journal of Clinical Investigation 1991, 88:1747-1754.
424
38 Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in
European intensive care units: Results of the SOAP study. Critical Care Medicine 2006, 34:344-353.
415
39 Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P: Septic shock, multiple organ
failure, and disseminated intravascular coagulation - compared patterns of antithrombin-III, protein-C, and
protein-S deficiencies. Chest 1992, 101:816-823.
414
40 Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riché F, Leleu G, Arbibe L,
Mignon A, Delpech M, Dhainaut JF: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock
susceptibility and mortality - A multicenter study. JAMA-Journal of the American Medical Association 1999, 282:561-568.
412
41 Marik PE, Sibbald WJ: Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA-Journal of
the American Medical Association 1993, 269:3024-3029.
411
42 Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric-oxide synthase inhibitor in humans
with septic shock. Cardiovascular Research 1994, 28:34-39.
410
43 Clowes GHA, George BC, Villee CA, Saravis CA: Muscle proteolysis induced by a circulating peptide in patients with
sepsis or trauma. New England Journal of Medicine 1983, 308:545-552.
407
44 Abraham E, Laterre P, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R,
Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL: Drotrecogin alfa (activated) for adults with severe sepsis
and a low risk of death. New England Journal of Medicine 2005, 353:1332-1341.
401
45 Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen
H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J,
Poole L, Stolzenbach JC, Creasey AA:Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in
severe sepsis - A randomized controlled trial. JAMA-Journal of the American Medical Association 2003, 290:238-247.
395
46 Noone P, Parsons TMC, Pattison JR, Slack RC, Garfield-Davies D, Hughes K: Experience in monitoring gentamicin therapy
during treatment of serious gram-negative sepsis. British Medical Journal 1974, 1:477-481.
384
47 Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D’Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency
contributes to the vasodilation of septic shock. Circulation 1997, 95:1122-1125.
383
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sepsis was weak in the related nine countries. This
might be due to the limited number of retrieved articles
and included countries. In addition, it was found that
American authors tended to cite local papers [11] and
US reviewers had a significant preference to accepting
papers written by native researchers [12]. Our study
found that most of the classics were published in high-
impact journals, which is consistent with the result of
other reviews, supporting the well known paradigm that
top cited articles are often published in journals topping
the impact factor list, which in turn maintains the high
impact factor of these journals [13].
Financial support from public foundations or commer-
cial companies has evolved over time in response to
changes in professional codes, laws and markets[14].
Public funds have given a great push to the development
of medical research and public health. In our study, 15
papers reported funding support from public institutions
or national foundations. Industry-funded science has
been widely debated because of the susceptibility to var-
ious kinds of biases. Nevertheless, it has played and will
continue to play a critical role in the research process
[15]. Our review shows that a total of 18 research pro-
jects received grants from ommercial companies. A
remarkable thing should be considered that some
papers, especially the old ones, might not have fully
reported their financial conflicts.
Clinical research has bridged the gap between basic
science and improved human health and is heavily
weighted towards biomedical science. In the past 40
years, clinical studies have tested large numbers of ther-
apeutic agents and provided insights into the pathophy-
siological basis of sepsis. The list of the top cited articles
shows some interesting trends and pinpoints major
advances in sepsis research. Sepsis has been defined as
hyper-inflammation and excessive activation of the
immune system characterized by a prolonged cytokine
storm. Therefore, many studies have targeted certain
cytokines highly expressed in sepsis for therapeutic or
diagnostic application. IL-6 and TNF-a appeared to be
good markers for predicting severity and prognosis of
sepsis. However, clinical trials have failed to demon-
strate promising results using antibody blockade to
these cytokines, for sepsis initiates much more complex
immunologic responses. Glucocorticoids have been
another hot topic in the field of sepsis research. Owing
to the positive effect on the sensitivity of vascular
smooth muscle to catecholamines, steroid has been con-
sidered as a promising agent in septic shock patients.
Currently, the use of glucocorticoid cannot be recom-
mended as the standard of care, but it is feasible in the
course for patients with septic shock that does not
respond to conventional measures.
Of the 19 RCTs, eight demonstrated promising and
supportive interventions [See Additional file 1]. Consid-
ering that RCT-based studies provide greater quality evi-
dence than other study designs, trials with promising
results often encourage clinicians to apply these inter-
ventions. Unfortunately, successful measures for sepsis
treatment seem difficult to achieve; in the top cited 50
articles, 11 of the 19 RCTs have proved to be non-effi-
cacious. Reasons related to the negative results include
the reporting quality of these studies, small sample size
or heterogeneity of the ICU patient population[16].
Table 1 The top 50 cited clinical trials on sepsis. (Continued)
48 Askanazi J, Carpentier YA, Elwyn DH, Nordenström J, Jeevanandam M, Rosenbaum SH, Gump FE, Kinney JM: Influence of
total parenteral-nutrition on fuel utilization in injury and sepsis. Annals of Surgery 1980, 191:40-46.
381
49 Michard F, Boussat S, Chemla D, Anguel N, Mercat A, Lecarpentier Y, Richard C, Pinsky MR, Teboul JL: Relation between
respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory
failure. American Journal of Respiratory and Critical Care Medicine 2000, 162:134-138.
372
50 Lorenz E, Mira JP, Frees KL, Schwartz DA: Relevance of mutations in the TLR4 receptor in patients with gram-negative
septic shock. Archives of Internal Medicine 2002, 162:1028-1032.
372
Table 2 Frequency distribution showing publication years
of the 50 top-cited articles.
Period Number of articles Mean number of citations
1970 to 1984 6 455
1985 to 1989 3 773
1990 to 1994 16 556
1995 to 1999 10 508
2000 to 2004 10 1593
2005 to present 5 522
Table 3 Countries of origin of the top 50 cited articles on
sepsis.
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Our review has several limitations. First, we elected to
limit our research to ‘sepsis’ or ‘septic shock’ in the
topic field, which may miss some citations related to
our analysis such as those indexed with ‘LPS’. In addi-
tion, our search via the Web of Science expanded data-
base from 1970 to present is quite sensitive and papers
published before were excluded, so it is likely that some
true ‘classic’ articles were missed in this review.
Another limitation is the inherent bias of the citation
analysis [17]. Total cites of an article accumulate over
time which means that older publications would defi-
nitely receive more citations than new ones. Recent pub-
lications with a short span of time to generate citation
rates are possibly underestimated with respect to their
impact. In addition, oriented or biased citing, including
self-citation, in-house, or negative citation (bias towards
potential negative credits) is also a problem that should
not be ignored [18]. An important thing to be kept in
mind is that impact factor or citation analysis is not an
index to evaluate the quality of scientific research, but
rather a measure of recognition. In other words, the
number of citations of an article should not be consid-
ered equivalent to its importance.
Conclusions
Our bibliometric analysis provides a historical perspec-
tive on the progress in clinical sepsis research in the
past 40 years. Papers originated from the US and pub-
lished in high-impact journals are most likely to be cited
in the field of sepsis research.
Key messages
• The mean number of citations per article was 678
and six papers were cited more than 1,000 times.
• The US is responsible for the most contributions
to clinical studies on sepsis.
• The top cited 50 articles on sepsis were published
in 17 journals, led by the New England Journal of
Medicine (n = 11) and the Journal of the American
Medical Association (n = 11), followed by Critical
Care Medicine (n = 6).
• About half of research papers received funding
support from public institutions or national
foundations.
• Nineteen articles were designed as RCTs, among
which eight papers reported promising results.
Additional material
Additional file 1: Therapy or agents tested in RCTs on sepsis.
Nineteen studies among the citation classics were designed as RCTs.
Treatments tested in eight articles were found to be promising or
supportive interventions.
Abbreviations
IF: impact factor; IL: interleukin; LPS: lipopolysaccharide; NIH: National
Institutes of Health; RCT: randomized controlled trial; TNF: tumor necrosis
factor.
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Table 4 Institutions of origin with three or more top-
cited articles on sepsis.
Rank Institution Number of articles
1 Rush University(Chicago) 6
2 University of Pittsburgh(Pennsylvania) 6
3 Brown University(Rhode Island) 5
4 University of Miami (Florida) 5
5 Cleveland Clinic Foundation(Cleveland) 3
6 Erasme University Hospital(Brussels) 3
Table 5 Journals in which the top 50 cited articles on
sepsis were published.




1 New England Journal of
Medicine
11 53.48
2 Journal of the American
Medical Association
11 30.01
3 Annals of Internal Medicine 2 16.72
4 Annals of Surgery 5 7.47
5 Chest 3 6.52
6 Critical Care Medicine 6 6.25
Table 6 The most common authors of top 50 cited









Sprung, CL. 6 2 0 0
Abraham, E 5 3 0 0
Fisher, CJ 5 2 2 1
Bone, RC 5 1 0 1
Balk, RA 5 0 1 1
Vincent, JL 4 1 2 0
Annane, D 3 2 0 0
Levy, H 3 0 0 0
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